Related Experiment Video
Updated: Feb 1, 2026
07:37
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
3.7K
Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
Liu Yang1, Geng Guo2, Xiao-yuan Niu1
1Department of Neurology, The First Hospital, Shanxi Medical University, No. 85 South Jie Fang Road, Taiyuan, Shanxi 030001, China.
Biomed Research International
|July 14, 2015
Summary
Dendritic cell (DC) vaccination shows promise for treating glioblastoma multiforme (GBM), a deadly brain cancer. This immunotherapy approach enhances the immune system
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer research
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor patient prognosis despite conventional treatments.
- Current therapies including surgery, chemotherapy, and radiation offer limited long-term survival benefits for GBM patients.
Purpose of the Study:
- To explore the potential of dendritic cell (DC)-based vaccination as a novel immunotherapy for glioblastoma multiforme.
- To evaluate how DC vaccination can enhance existing GBM treatments and improve patient outcomes.
Main Methods:
- Utilizing dendritic cells (DCs), potent antigen-presenting cells, to stimulate an immune response against GBM.
- Investigating strategies to optimize DC vaccination efficacy, including antigen selection and manipulation of the tumor microenvironment.
Main Results:
- DC-based vaccination can enhance the immune system's recognition and elimination of GBM cells.
- This immunotherapy approach has the potential to work synergistically with conventional therapies, minimizing damage to healthy tissues.
Conclusions:
- Dendritic cell vaccination represents a promising therapeutic strategy for glioblastoma multiforme, offering a potential for prolonged patient survival.
- Further research into optimizing DC vaccination, including immune regulatory manipulation, holds significant potential for future GBM treatment.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.4K
10:52Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme
Published on: September 25, 2012
26.5K
Related Concept Videos
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
01:23Neurons: The Cell Body and the Dendrites
7.1K
A typical nerve cell comprises three main components: the cell body, dendrites, and the axon. The cell body, also known as the soma or perikaryon, serves as the central biosynthetic hub housing a nucleus surrounded by cytoplasm containing organelles commonly found in most cells. Notably, Nissl bodies, clusters of the rough endoplasmic reticulum and free ribosomes responsible for protein synthesis, are distinctive features of the neuronal cell body. As neurons age, aggregates of a brown pigment...
7.1K
01:27Open Angle Glaucoma: Treatment
996
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
996
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:24Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
01:22Alzheimer's Disease: Treatment
956
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
956